Delphi Technologies, a producer of auto parts, in its pending all-stock sale to BorgWarner valued at $3.3 billion.
Bristol-Myers Squibb in its $90 billion acquisition of Celgene, the largest-ever acquisition of a pharmaceutical company, and its related $13.4 billion divesture of Celgene’s OTEZLA® program to Amgen.
Bristow Group, a provider of industrial aviation services, in its all-stock merger with Era Group.
Ten-X, a Thomas H. Lee Partners portfolio company that offers an online platform for commercial real estate transactions, in its $190 million sale to CoStar.
A private equity sponsor in its acquisition of a hospice provider.
PEC Safety, a Thoma Bravo portfolio company, in its merger with a provider of supply chain risk management and compliance solutions.
Liqui-Box, an Olympus Partners portfolio company that provides flexible packaging solutions, in its $585M acquisition of DS Smith’s plastics division.
SoftBank Vision Fund in its investment in ParkJockey (now REEF Technology), a provider of parking technology solutions, and ParkJockey’s acquisition (with Mubadala) of parking facility operators Citizens Parking and Imperial Parking.
Kofax, a Thoma Bravo portfolio company that provides business process software, in its $400 million acquisition of Nuance Document Imaging.
TriMedx, a TowerBrook Capital Partners portfolio company that provides clinical asset management solutions for the healthcare industry, in its $300 million acquisition of Aramark Healthcare Services.
Riskonnect, a Thoma Bravo portfolio company that offers risk management technology solutions, in its acquisition of Marsh ClearSight.
Tronox, a vertically integrated producer of titanium dioxide and inorganic chemicals, in its $2.2 billion acquisition of Cristal’s titanium dioxide business, and litigation by the Federal Trade Commission seeking to block the transaction.
Thoma Bravo in its acquisitions and merger of MeridianLink and CRIF Lending Solutions, which provide software solutions to financial institutions.
Chesapeake IRB (now Advarra), a Linden Capital Partners portfolio company that provides research compliance solutions, in its merger with Schulman IRB.
Huntsman in its proposed merger with Clariant with a combined enterprise value of approximately $20 billion.
Creat Group in its €940 million public takeover of Biotest, a producer of human blood plasma products.
WellCare in its $800 million acquisition of Universal American, a provider of Medicare Advantage plans.
Zydus Pharmaceuticals in civil litigation relating to alleged price-fixing of generic drugs.
Numerous private equity clients and their portfolio companies, on antitrust matters in connection with confidential transactions.
Italcementi and Italmobiliare in the $4.1 billion acquisition of Italcementi by HeidelbergCement.*
Abbott Laboratories in its $25 billion acquisition of St. Jude Medical, and its related $1.1 billion divestiture of certain vascular closure products and other assets to Terumo.*
Teladoc in litigation against the Texas Medical Board successfully challenging the board’s actions to restrict competition.*
Gilead Sciences in winning dismissal of a purported class action alleging unfair competition and Affordable Care Act violations.*
Goldman Sachs in multiple civil litigations and government investigations relating to residential mortgage-backed securities.*
*Prior to joining Kirkland
